- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 29
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure
- Interventions
- Canagliflozin 100 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 18
- States / cities
- Fort Smith, Arkansas • Aurora, Colorado • Clearwater, Florida + 15 more
- Conditions
- Diabetes Mellitus, Type 2, Albuminuria
- Interventions
- Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 5,813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 57
- States / cities
- Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
- Conditions
- Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
- Interventions
- Canagliflozin (JNJ-28431754), Sitagliptin, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
- Conditions
- Healthy Volunteers
- Interventions
- Placebo, Canagliflozin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Obesity
- Interventions
- Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
- Interventions
- Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 4,330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 55 more
- Conditions
- Diabetes, Obesity
- Interventions
- Canagliflozin
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- San Diego, La Jolla, California • Gainesville, Florida
- Conditions
- Diabetes Mellitus, Type 2, Renal Insufficiency
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 26
- States / cities
- Concord, California • Fountain Valley, California • San Diego, California + 23 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 46
- States / cities
- Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Encino, California • Huntington Park, California • Los Angeles, California + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 50 mg, Placebo, Canagliflozin 150 mg, Metformin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • National City, California • Spring Valley, California + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, Placebo, Metformin, Sulphonylruea
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more
- Conditions
- Diabetes Mellitus, Type 2, Obesity
- Interventions
- canagliflozin, Placebo (for canagliflozin)
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Obesity
- Interventions
- Canagliflozin (JNJ-28431754), Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 35
- States / cities
- Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more
- Conditions
- Type2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
- Canagliflozin 300mg, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Chula Vista, California • San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 41
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more